Colorectal Cancer Vaccines: Antiidiotypic Antibody, Recombinant Protein, and Viral Vector

: The colorectal cancer antigen GA733 (also termed CO17‐1A, KSI‐4, Ep‐CAM, KSA) has proved to be a useful target in passive immunotherapy with monoclonal antibody and in active immunotherapy with antiidiotypic antibodies in cancer patients. The GA733 antigen was molecularly cloned and expressed in baculovirus (BV), adenovirus (AV), and vaccinia virus (VV). Recombinant BV‐, VV‐, and AV‐GA733 induced antigen‐specific cytotoxic antibodies and proliferative and delayed‐type hypersensitive lymphocytes. However, only the AV recombinant induced antigen‐specific cytolytic T lymphocytes and regression of established tumors. Cured mice were protected against challenge with antigen‐negative tumors, indicating antigen spreading of immune responses. In a model of active immunotherapy against the murine homologue of the human GA733 antigen, murine epithelial glycoprotein (mEGP), BV‐derived mEGP protein in various adjuvants did not protect mice against a challenge with mEGP‐positive tumors. AV mEGP, only when combined with interleukin‐2, significantly inhibited growth of established mEGP‐positive tumors. This is in contrast to the same vaccine expressing the human antigen that was effective without interleukin‐2. AV GA733, in combination with interleukin‐2, is a candidate vaccine for colorectal cancer patients.